Conference Series LLC LTD organizes 1000+ Conferences every year across USA, Europe & Asia with support from 1000 more scientific societies and publishes 1000+ Open access journals which contain over 70000 eminent personalities, reputed scientists as editorial board members, 1200 Symposium & Workshops and 5 million followers. Conference Series Ltd invites all the participants across the globe to attend the 1st Webinar on biosimilars in September 21,2021.
WEBINAR ON BIOSIMILARS 2021 conveys recent developments in Pharma drug marketing and production of Pharma drugs and contract manufacturing. A complete knowledge of a scientific discipline that described the effects of Biosimilars drug marketing and Biosimilars Pharma now explores the Scope of Biosimilars drug marketing in industry. Biosimilars 2021 provides detailed market, technology, and industry analyses to help readers quantify and qualify the market for prescription generic drugs. Important trends are identified and sales forecasts by product categories and major country markets these are based on industry sources and considered assessment of the regulatory environment, healthcare policies, demographics, and other factors that directly affect the generic drug market. The wider economic environment is also considered.
Why attend WEBINAR ON BIOSIMILARS 2021:
-
Keynote presentation along with interactions to galvanize the scientific community.
-
Workshop and symposiums to reach the largest assemblage of participants from the Pharma/Biotech community.
-
A wide track of exhibitors to showcase the new and emerging technologies.
-
Platform to global investment community to connect with stakeholders in Pharma/Biotech sector.
-
Young Scientist/ Investigators Award geared towards best budding young research.
-
Links to the political marketing resources to expand your business and research network.
-
Triumph of Awards, Certificates recognizes your commitment to your profession to encourage the nascent research.
​Target Audience:
-
Directors, CEO’s of Organizations
-
Business Development Managers
-
Chief Scientific Officers
-
R&D Researchers from Biosimilar and Biologics Industries
-
Professors, Associate Professors, Assistant Professors
-
PhD Scholars
-
Patent Attorneys
-
Intellectual Property Attorneys
-
Investment Analysts
-
Association, Association presidents and professionals
-
Noble laureates in Health Care and Medicine
-
Bio instruments Professionals
-
Bio-informatics Professionals
-
Software development companies
-
Research Institutes and members
-
Supply Chain companies
-
Manufacturing Companies
-
CRO and DATA management Companies
-
Training Institutes
-
Business Entrepreneurs
Biosimilars 2021has everything you need:
Open panel discussions: Providing an open forum with experts from academia and business to discuss on current challenges in Biosimilars & Biologics, where all attendees can interact with the panel followed by a Q&A session.
Speaker and poster presentations: Providing a platform to all academicians and industry professionals to share their research thoughts and findings through a speech or a poster presentation.
Editorial board meeting: Discussing on growth and development of open access Bioanalysis & Biomedicine International Journals and recruiting board members and reviewers who can support the journal.
Round table meetings: Providing a platform where industry professionals meet academic experts.
Over 50+ organizations and international pavilions will be exhibiting at the pharma Biosimilars 2019 conference. Exhibitors will include equipment manufacturers and suppliers, systems providers, finance and investment firms, R&D companies, project developers, trade associations, and government agencies.
In addition to the products and services you will have access to valuable content, including Keynote Presentations, Product Demonstrations and Educational Sessions from today’s industry leaders.
The Biosimilars 2021 has everything you need, all under one roof, saving you both time and money. It is the event you cannot afford to miss!
A two-day gathering that examines the future market patterns, creative business methodologies and open doors for development of moderate medications. Pharma pioneers want the substance and roundtable examinations yet remain for the systems administration and air. This meeting is formally the biggest key nonexclusive gathering in the business and will give members a thorough survey of business methodology for moderate meds.
Sessions 1: Analytical Strategies of Biosimilar
Biologics and Biosimilar analysis make the one of the most important aspect on the development on biological products. The use of production technologies such as disposable and supply chain logistics can help companies such establish flexibility facility involved in biosimilar analytical methods.
Bioanalytical methods include in all global events of biosimilars for example: GMP protein analysis, pre-clinical and clinical program, Bioassay for comparability and potency testing.
Sessions2: Emerging Biosimilars In Therapeutics
In the field of biologics, the new avenue has created towards clinicians because explorations have created for better disease management. In the treatment of ailments like psoriasis, rheumatic arthritis, certain cancer inflammation, bowel diseases etc. showed some good outcomes because of using biologics. Biosimilar insulins which are newly formed are likely to enter the insulin landscape as patents for major branded insulin products ready to expire in the next few years. The emerging biosimilar like filgrastim, peg filgrastim, recombinant blood products, therapeutic products vaccine biosimilar, anti-bodies growth hormones, biosimilar peptide, all these are used to sound knowledge on biosimilars development on drugs.
Sessions3: Current Challenges in Developing Biosimilars
For the development of biological calls many changes may occur. Concepts of biologics with considerations at initial stages, clinical developments are essential at early. For the successful development of biologics follow on proper scientific and strategic approaches are need. Most probably, the drug safety factors and labelling requirements are the overcoming challenges and important in continue of late clinical steps. And now it is much required to develop a drug product in according to quality by design.
Track 4: Regulatory Approaches of Biosimilars
biosimilars is likewise called as nonspecific adaptation of biosimilars. The clinically idle compound is not withstanding with biosimilars but rather minor contrasts and profoundly like authorized item; additionally, there Presently a-days in pharmaceutical industry biosimilars is shaped has another buzz. Furthermore, these are no clinically important contrasts between the biologicals and the reference item as far as intensity, wellbeing and immaculateness. The worldview of customary generics to biosimilars, and different parts of Biosimilar endorsements. Also, these Biosimilars 2019 will give a phenomenal and overall chance to the researchers, accomplices and pharma pioneers from Biopharmaceutical and Biotechnology businesses to improve and to investigate the key market for Biosimilars and Biologics with an unmistakable photo of the administrative approach for biosimilars and biologics.
Sessions5: Pharmacovigilance challenges in Biosimilars
Same proportion pharmacovigilance for biosimilars has comparatively more different from other products. Biosimilars 2019 session mainly look that have already been announced to include enhanced tracking and follow-up of post marketing surveillance issues, and on FDA initiative planned different changes in AERS, pilots of new developed post market strategies of drug-monitoring and ADR related problems. The guidelines of biosimilars for pharmacovigilance and pharma epidemiology are the points that shall be laid emphasis in the session In USA average annual income mostly spend on biologics comparing to generic drugs for example:16% on biologics and 3% on other drugs.
Sessions 6: BCS and IVIVC Based on Biosimilars
These Mainly discusses about different types of drugs and adsorption distribution metabolism excretion pathways. And This biosimilars includes, In vitro diffusion cells for dissolution testing in formulation development, The preclinical testing of ADME in INVITRO. The primary moto of this work was to suggest the biosimilars potential of biopharmaceutical classification system which are known to increase the dissolution. These insoluble drugs which is orally absorbed. These Aims at addressing all such challenges of the pharma formulation sector at biologics and biosimilars at 2019 conference. The solubility includes in biopharmaceutical classification.
Sessions 7: Globalization of Bio Similar
These tracks mainly deal with biosimilar meetings those who can attend by following biologics/protein/biosimilar product process science, New biosimilar development, portfolio Management, Reasearch&development, biosimilar market, business operations, scientific affairs. This track mainly discusses about Risk-sharing arrangement LATAM market for bio-similar adopting innovative mechanism for generic drugs impact on global bio similar market and cost and riskmanagement.
